Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Clinical decision support tool for phototherapy initiation in preterm infants

Abstract

Objective

Adherence to guidelines for phototherapy initiation in preterm infants was 39% in our academic NICU (61% of phototherapy was initiated at total bilirubin (TB) levels below recommended thresholds). We hypothesized that adoption of an electronic health record integrated clinical decision support (CDS) tool would improve adherence to phototherapy guidelines.

Study design

We developed and implemented Premie BiliRecs (PBR), a novel CDS tool for phototherapy initiation in preterm infants from 27 through 34 weeks postmenstrual age. The primary outcome measure was the proportion of phototherapy initiation events consistent with recommended TB thresholds.

Result

Following the implementation of PBR, adherence to guidelines for phototherapy initiation in preterm infants increased to 69.8% (p < 0.001), an improvement of 77%. There was no increase in the incidence of severe hyperbilirubinemia nor exchange transfusions.

Conclusion

The adoption of PBR was associated with improved adherence to phototherapy guidelines in preterm infants without increased adverse events.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2: Premie BiliRecs was implemented in the EHR in January 2016.

References

  1. 1.

    Bhutani VK, Wong RJ, Stevenson DK. Hyperbilirubinemia in preterm neonates. Clin Perinatol. 2016;43:215–32.

    Article  Google Scholar 

  2. 2.

    Ramy N, Ghany EA, Alsharany W, Nada A, Darwish RK, Rabie WA, et al. Jaundice, phototherapy and DNA damage in full-term neonates. J Perinatol. 2016;36:132–6.

    CAS  Article  Google Scholar 

  3. 3.

    Sirota L, Straussberg R, Gurary N, Aloni D, Bessler H. Phototherapy for neonatal hyperbilirubinemia affects cytokine production by peripheral blood mononuclear cells. Eur J Pediatr. 1999;158:910–3.

    CAS  Article  Google Scholar 

  4. 4.

    Wickremasinghe AC, Kuzniewicz MW, Grimes BA, McCulloch CE, Newman TB. Neonatal phototherapy and infantile cancer. Pediatrics. 2016;137:e20151353.

    Article  Google Scholar 

  5. 5.

    Tyson JE, Pedroza C, Langer J, Green C, Morris B, Stevenson D, et al. Does aggressive phototherapy increase mortality while decreasing profound impairment among the smallest and sickest newborns? J Perinatol. 2012;32:677–84.

    CAS  Article  Google Scholar 

  6. 6.

    Morris BH, Oh W, Tyson JE, Stevenson DK, Phelps DL, O’Shea TM, et al. Aggressive vs. conservative phototherapy for infants with extremely low birth weight. N Engl J Med. 2008;359:1885–96.

    CAS  Article  Google Scholar 

  7. 7.

    American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114:297–316.

    Article  Google Scholar 

  8. 8.

    Longhurst C, Turner S, Burgos AE. Development of a Web-based decision support tool to increase use of neonatal hyperbilirubinemia guidelines. Jt Comm J Qual Patient Saf. 2009;35:256–62.

    PubMed  Google Scholar 

  9. 9.

    Bratlid D, Nakstad B, Hansen TW. National guidelines for treatment of jaundice in the newborn. Acta Paediatr. 2011;100:499–505.

    CAS  Article  Google Scholar 

  10. 10.

    Maisels MJ, Watchko JF, Bhutani VK, Stevenson DK. An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation. J Perinatol. 2012;32:660–4.

    CAS  Article  Google Scholar 

  11. 11.

    Silveira PC, Sumption S, Raja AS, Tajmir S, Khorasani R. Impact of a clinical decision support tool on adherence to the Ottawa Ankle Rules. Am J Emerg Med 2016;34:412–8.

    Article  Google Scholar 

  12. 12.

    Tierney, WM. Improving clinical decisions and outcomes with information: review. Int J Med Inform, 2001;62:1–9.

  13. 13.

    Electronic Medical Record Adoption Model. https://www.himssanalytics.org/emram. Published 2017. Accessed April 24, 2019.

  14. 14.

    Palma JP, Arain YH. Development of a web-based decision support tool to operationalize and optimize management of hyperbilirubinemia in preterm infants. Clin Perinatol. 2016;43:375–83.

    Article  Google Scholar 

  15. 15.

    Wallenstein MB, Bhutani VK. Jaundice and kernicterus in the moderately preterm infant. Clin Perinatol. 2013;40:679–88.

    Article  Google Scholar 

  16. 16.

    Bhutani VK, Wong RJ. Bilirubin neurotoxicity in preterm infants: risk and prevention. J Clin Neonatol. 2013;2:61–69.

    Article  Google Scholar 

  17. 17.

    National Collaborating Centre for Women’s and Children’s Health. Neonatal Jaundice. London, England: Royal College of Obstetricians and Gynaecologists; 2010.

  18. 18.

    Greene SM, Reid RJ, Larson EB. Implementing the learning health system: from concept to action. Ann Intern Med. 2012;157:207–10.

    Article  Google Scholar 

Download references

Acknowledgements

In addition to the Stanford neonatology division and the Stanford Children’s Health Information Services department, the authors wish to acknowledge Gomathi Krishnan, PhD and the Stanford Center for Clinical Informatics for their assistance in extracting the clinical data required to make this project possible.

Author information

Affiliations

Authors

Contributions

YA and JP conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript. JB and JF collected data, carried out the initial analyses, and reviewed and revised the manuscript. VB conceptualized and designed the study, supervised data collection, and critically reviewed the manuscript for important intellectual content. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Corresponding author

Correspondence to Jonathan P. Palma.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics

This project was reviewed and approved by the Stanford University School of Medicine Institutional Review Board. No protected health information is transmitted between the EHR and the web-based CDS tool. The CDS tool guidelines were extrapolated from existing expert-consensus guidelines, but we implemented safeguards to decrease the potential for inappropriate use and unintended consequences. Because lower treatment thresholds are required shortly after birth, the PBR homepage displays a reminder that the tool is not intended for use in infants less than 48 h of age, and we prevented the EHR-integrated link to PBR from displaying in patients less than 48 h of age.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Arain, Y., Banda, J.M., Faulkenberry, J. et al. Clinical decision support tool for phototherapy initiation in preterm infants. J Perinatol 40, 1518–1523 (2020). https://doi.org/10.1038/s41372-020-00782-0

Download citation

Search

Quick links